Abstract
Systemic Lupus Erythematosus (SLE) is a chronic inflammatory autoimmune disease that effects approximately 1 out of every 1000 individuals in the United States. Auto-antibodies are produced when improper destruction of apoptotic cells results in B-cell activation and differentiation. Since the auto-antibodies are secreted by mature B-cells, the complement system has long been a target of interest in treating SLE. Along with our collaborators, we have identified antibodies that have been shown to reverse the symptoms of SLE in a mouse model of lupus. In order to use this antibody as a potential therapeutic or imaging agent we have engineered a single chain variable fragment (scFv). After expressing the scFv in mammalian cells, subsequent purification resulted in high yields of pure protein. Binding affinities were measured and represent a valid approach to replace the much larger antibody.